Vitrafy enters partnership with Versiti Blood Health
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Vitrafy Life Sciences Ltd has announced a partnership with Versiti Blood Health to advance the development of its cryopreservation ecosystem for platelets. This collaboration follows a successful in-vitro platelet study conducted with the United States Army Institute of Surgical Research. Under the partnership, both companies will contribute resources to enhance no-wash platelet cryopreservation within Versiti's workflows. Vitrafy will place cryopreservation units at Versiti's facility in Milwaukee, Wisconsin, to support verification and validation activities for its medical device listing.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Vitrafy Life Sciences Ltd. on 6ix
Earlier from Vitrafy Life Sciences
- S&P DJI Announces September 2026 Quarterly Rebalance
- Vitrafy enters U.S. Cell & Gene Therapy Market
- FY26 Full Year Results Presentation
- FY26 Appendix 4E and Annual Report
- FY26 Corporate Governance Statement
Later from Vitrafy Life Sciences
- Change to CEO Remuneration and Employment Terms
- Investor Roadshow Presentation
- 2026 Notice of Annual General Meeting
- Appointment of Chief Financial Officer
- Application for quotation of securities - VFY
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences